Federal prosecutors drop the charges against former Stryker Biotech president Mark Philip as new evidence crops up in a lawsuit alleging that the company illegally promoted off-label use of combination of two bone growth products and lied to the FDA.

Federal prosecutors dropped all charges against former Stryker Biotech president Mark Philip today in a lawsuit charging him and a clutch of sales reps with illegally promoting the off-label use of 2 bone growth products and of lying to the FDA.
The feds dropped the Philip indictment after reviewing documents that had previously been withheld as privileged, assistant U.S. attorney Jeremy Sternberg said during a pretrial hearing today, according to Bloomberg.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...